生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

已收盘 01-08 16:00:00

6,157.789

-0.141

+0.00%

最高6,245.548	最低6,134.351	成交量2.10亿
今开6,158.186	昨收6,157.930	日振幅1.81%
总市值0.00	流通市值0.00	总股本0.00
成交额76.07亿	换手率--	流通股本0.00
市净率8.04704	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":6157.789,"timestamp":1767859687811,"preClose":6157.93,"halted":0,"volume":210443791,"delay":0,"changeRate":-0.000023,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.141113,"latestTime":"01-08 16:00:00","open":6158.186,"high":6245.5483,"low":6134.3506,"amount":7606689057,"amplitude":0.018058,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767922200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1767835800000,1767844800000],[1767848400000,1767859200000]],"pbRate":8.04704,"peRate":-80.860427,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2601363983","title":"绿叶制药(02186)：1类创新药若欣林®用于治疗广泛性焦虑障碍的新适应症中国上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363983","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363983?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:03","pubTimestamp":1767870230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，中国国家药品监督管理局药品审评中心已正式受理本集团1类创新药若欣林的新适应症上市申请，拟用于治疗广泛性焦虑障碍。这是该产品自2022年11月获批上市用于治疗抑郁症后的又一里程碑。该研究纳入555例患者，以汉密尔顿焦虑量表总分较基线变化为主要终点，评估若欣林治疗广泛性焦虑障碍的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","06978","159992","BK1574","BK1583","BK1606","02186"],"gpt_icon":0},{"id":"2601486352","title":"中物联：12月中国仓储指数为52.4% 较上月回升2个百分点","url":"https://stock-news.laohu8.com/highlight/detail?id=2601486352","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601486352?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:24","pubTimestamp":1767864243,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国物流与采购联合会与中储发展股份有限公司联合调查的中国仓储指数，2025年12月份为52.4%，较上月回升2个百分点。中储发展股份有限公司副总经理杨飚认为：12月仓储指数明显回升，达到2月份以来的新高。期末库存指数为51.9%，较上月上升1.9个百分点。平均库存周转次数指数为53.4%，较上月上升3.4个百分点。业务活动预期指数为52.7%，较上月下降2.6个百分点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2601531357","title":"每日卖空追踪 | 科笛-B 01月08日卖空量成交3400股，卖空比例为1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601531357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601531357?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861032,"startTime":"0","endTime":"0","summary":"科笛-B北京时间01月08日，跌1.33%，卖空量成交3400股，较上一交易日减少10.53%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164831a4ab462e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164831a4ab462e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02487"],"gpt_icon":0},{"id":"2601350431","title":"每日卖空追踪 | 和誉-B 01月08日卖空量成交6.5万股，卖空比例为4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601350431","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601350431?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861030,"startTime":"0","endTime":"0","summary":"和誉-B北京时间01月08日，跌0.56%，卖空量成交6.5万股，较上一交易日减少74.1%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164655a4ab44f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164655a4ab44f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274720.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2778985437.USD","IE00B5MMRT66.SGD","LU2488822045.USD","BK1161","LU2476274308.USD","02256"],"gpt_icon":0},{"id":"2601836898","title":"每日卖空追踪 | 乐普生物-B 01月08日卖空量成交18万股，卖空比例为2.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601836898","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601836898?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861029,"startTime":"0","endTime":"0","summary":"乐普生物-B北京时间01月08日，跌1.82%，卖空量成交18万股，较上一交易日减少80.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164617a7023c6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164617a7023c6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02157","BK1161"],"gpt_icon":0},{"id":"2601526363","title":"每日卖空追踪 | 歌礼制药-B 01月08日卖空量成交27.7万股，卖空比例为9.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601526363","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601526363?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861025,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间01月08日，涨1.05%，卖空量成交27.7万股，较上一交易日减少25.14%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164538a7023b88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164538a7023b88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1574","BK1161","01672","BK1191","BK1515"],"gpt_icon":0},{"id":"2601695368","title":"乐普生物-B01月08日主力净流出204.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2601695368","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601695368?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:15","pubTimestamp":1767860153,"startTime":"0","endTime":"0","summary":"01月08日, 乐普生物-B股价跌1.82%，报收5.38元，成交金额3496.3万元，换手率0.36%，振幅3.83%，量比0.81。乐普生物-B今日主力资金净流出204.2万元，上一交易日主力净流入61.2万元。该股近5个交易日上涨7.85%，主力资金累计净流入55.8万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出466.6万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162646a4ab3040&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162646a4ab3040&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02157"],"gpt_icon":0},{"id":"2601356455","title":"1月8日三博脑科涨5.39%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356455","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356455?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:41","pubTimestamp":1767858095,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日三博脑科涨5.39%创60日新高，收盘报98.88元，换手率36.91%，成交量59.4万手，成交额56.87亿元。重仓三博脑科的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为5.03亿元，最新净值0.6103，较上一交易日上涨1.5%，近一年上涨27.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","159938","301293","BK0236","BK1161","BK1574"],"gpt_icon":0},{"id":"2601540653","title":"国元国际：宜明昂科-B(01541)重获IMM2510全球权利 海外研发有望加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2601540653","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601540653?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:09","pubTimestamp":1767856165,"startTime":"0","endTime":"0","summary":"公司与Axion订立终止协议，收回此前授予Axion的全球开发及商业化权利，仅保留Axion逐步结束临床开发活动的有限许可。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260108/20260108151004_11502.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260108/20260108151004_11502.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2601356555","title":"2026开年已经有3款创新药密集获批上市，来自恒瑞、百济、赛诺菲","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356555","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356555?lang=zh_cn&edition=full","pubTime":"2026-01-08 13:44","pubTimestamp":1767851095,"startTime":"0","endTime":"0","summary":"2026新年伊始，医药行业便传来阵阵暖意，根据国家药品监督管理局网站消息，2026开年已经有三款创新药获批上市，其中包含2个国产创新药，分别来自恒瑞医药、百济神州；1个进口产品，来自赛诺菲。业内表示，本次普乐司兰钠注射液的获批，回应了临床在甘油三酯管理方面的迫切患者需求。开年三款创新药的密集获批，离不开国家利好政策的支持。回顾刚刚过去的2025年，我国有76个创新药获批上市，与2024年48个相比，大幅增长58.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108134829a4aaa790&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108134829a4aaa790&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU2328871848.SGD","BK1161","06160","LU1770034418.SGD","LU1969619763.USD","LU0588546209.SGD","BK1574","BK1588","LU1303224171.USD","LU1719994722.HKD","BK1500","06978","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2601562331","title":"港股异动 | 复宏汉霖(02696)盘中涨超5% 公司首次公布PD-L1 ADC食管鳞状细胞癌Ⅱ期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2601562331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601562331?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:18","pubTimestamp":1767842338,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53万港元。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项Ⅱ期研究旨在评估HLX43用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK4080","02696","LU1169590202.USD","LU1169589451.USD","ADC","BK4023","PD","BK1161","BK4231"],"gpt_icon":0},{"id":"2601933748","title":"亿胜生物科技盘中异动 大幅上涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601933748","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601933748?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:07","pubTimestamp":1767841659,"startTime":"0","endTime":"0","summary":"2026年01月08日早盘11时07分，亿胜生物科技股票出现波动，股价大幅拉升5.32%。截至发稿，该股报4.160港元/股，成交量27.5万股，换手率0.05%，振幅5.32%。亿胜生物科技股票所在的药品行业中，整体跌幅为0.17%。亿胜生物科技公司简介：亿胜生物科技有限公司是一家主要从事生产及销售治疗体表创伤和眼部损伤生物药品的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010811073997a13b28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010811073997a13b28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01061"],"gpt_icon":0},{"id":"2601508673","title":"中欧基金葛兰2025年三季度坚守医药板块，多只标的获增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2601508673","media":"财经杂谈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601508673?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:05","pubTimestamp":1767841535,"startTime":"0","endTime":"0","summary":"随着公募基金2025年三季度报披露完毕，中欧基金葛兰的投资布局与调仓动向受到市场广泛关注。从整体业绩来看，三季度期间，葛兰旗下三只基金均大幅跑赢同期业绩比较基准。信立泰首次出现在中欧医疗创新前十大重仓股名单中，该个股此前二季度期间位于其隐形重仓股行列。对于行业前景与投资布局，葛兰在三季报中指出，医药行业的长期发展核心驱动力依然在于创新升级、消费复苏及国产化替代。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108120245a7014cd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108120245a7014cd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1191","09939","BK1161","06821"],"gpt_icon":0},{"id":"2601336363","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336363","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601336363?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:10","pubTimestamp":1767838222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","BK1574","09966"],"gpt_icon":0},{"id":"1114259311","title":"港股异动 | 医药股走高，加科思-B涨超8%，和铂医药-B涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114259311","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114259311?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:04","pubTimestamp":1767837899,"startTime":"0","endTime":"0","summary":"1月8日，港股医药股走高，$加科思-B$涨超8%，$和铂医药-B$涨超7%，$映恩生物-B$、$复宏汉霖$涨超5%。消息面上，1月7日，从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02142","01167","BK1161","09939","BK1515","159938","BK1574"],"gpt_icon":0},{"id":"2601351333","title":"交易总额突破1300亿美元！2025年全球创新药BD交易全景分析及趋势预判","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351333","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601351333?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:55","pubTimestamp":1767837325,"startTime":"0","endTime":"0","summary":"本文将基于药渡咨询的深度调研数据，对2025年全球及中国创新药BD交易的全景进行深度剖析，并对未来五年的发展趋势进行前瞻性预判。全景回顾：全球与中国BD交易的双向奔赴1.交易规模：中国领跑全球增长2025年，全球生物医药BD授权交易呈现出显著的回暖与扩张态势。此次交易总金额高达42.3亿美元，直接推动荣昌生物股价在两周内涨幅超105%。结 语2025年标志着中国创新药BD交易从“量变”走向“质变”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","BK1161","02615"],"gpt_icon":0},{"id":"2601271336","title":"嘉和生物盘中异动 股价大跌5.47%报2.940港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601271336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601271336?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:31","pubTimestamp":1767835902,"startTime":"0","endTime":"0","summary":"2026年01月08日早盘09时31分，嘉和生物股票出现异动，股价大幅下挫5.47%。截至发稿，该股报2.940港元/股，成交量8.55万股，换手率0.00%，振幅2.25%。资金方面，该股资金流入1.05万港元，流出24.08万港元。嘉和生物股票所在的生物技术行业中，整体涨幅为0.99%。其相关个股中，加科思-B、复宏汉霖、昭衍新药涨幅较大，振幅较大的相关个股有拨康视云-B、加科思-B、昭衍新药，振幅分别为5.15%、4.65%、3.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108093143a700bb27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108093143a700bb27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","06998","BK1574"],"gpt_icon":0},{"id":"2601808383","title":"港股概念追踪|国家药监局优化临床急需境外已上市药品审评审批    创新药高景气度延续（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808383","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601808383?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:07","pubTimestamp":1767830855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，记者从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。公告显示，国家药监局将优化审评机制，加快审评速度;同时，也将完善检验制度，体现品种特点。据了解，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","09926","00013","LU2399975544.HKD","LU1720050803.USD","BK1587","LU2488822045.USD","159992","LU0348783233.USD","LU2476274308.USD","LU0417516738.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU0417516902.SGD","LU0348735423.USD","LU0417516571.SGD","LU0348766576.USD","LU0348784397.USD","06978","LU0348767384.USD","LU2778985437.USD","LU0348825331.USD","BK1191","BK1574","BK1161","LU0348827113.USD","LU1961090484.USD","BK1588","LU0561508036.HKD","LU2476274720.SGD","LU0634319403.HKD"],"gpt_icon":0},{"id":"2601536899","title":"67股发布2025年度业绩公告 报喜比例超七成","url":"https://stock-news.laohu8.com/highlight/detail?id=2601536899","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601536899?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:05","pubTimestamp":1767830700,"startTime":"0","endTime":"0","summary":"人民财讯1月8日电，1月7日晚间，16股发布2025年度业绩相关公告，其中川金诺、泉阳泉、北方导航、高能环境、康辰药业、中科蓝讯6股业绩预增，报喜比例为37.5%。截至目前，已有67股发布2025年度业绩相关公告，其中47股实现归母净利润同比增长或扭亏，报喜比例超过七成。从预告净利润同比增幅下限来看，中科蓝讯、百奥赛图、传化智联、康辰药业4股预告净利润同比增幅居前，均超过200%。分行业来看，上述预增或扭亏的47股中，属于基础化工行业的最多，共7股；其次是机械设备、电子、有色金属，分别有6股、5股、4股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108080613953c2ccf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108080613953c2ccf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2601333305","title":"26ASCO GI丨复宏汉霖首次公布PD-L1 ADC食管鳞癌Ⅱ期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2601333305","media":"药研网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601333305?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:00","pubTimestamp":1767830431,"startTime":"0","endTime":"0","summary":"2026年ASCO GI会议即将在召开，官方公布了本次胃肠道肿瘤研讨会摘要内容。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43 是靶向 PD-L1 的新型 ADC 药物，兼具免疫检查点抑制与细胞毒性双重作用，其 I 期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项 Ⅱ 期研究旨在评估 HLX43 用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108082422a4a988c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108082422a4a988c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0323},{"period":"1month","weight":0.0269},{"period":"3month","weight":-0.011},{"period":"6month","weight":0.0961},{"period":"1year","weight":0.3605},{"period":"ytd","weight":0.0323}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}